top of page

Redx Pharma identifies drug development candidate for leukaemia program

Redx Pharma has identified a drug development candidate for its reversible Bruton’s Tyrosine Kinase (BTK) inhibitor program.

The compound, named RXC005, has the potential to treat the majority of patients suffering from Chronic Lymphocytic Leukaemia (CLL), including those who become resistant to the increasingly used treatment Ibrutinib.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page